Physician
Oncology
Dr. Kathleen J. Yost, MD
|
|
Give Review
Dr. Kathleen J. Yost works in the field of Oncology. She graduated from University of Michigan Medical School. She has 1 awards "CMS Meaningful Use Stage 1 Certification". Dr. Kathleen J. Yost is a published physician as well. She has 47 publications published. The latest was: Adapting a Cancer Literacy Measure for Use Among Navajo Women. Kathleen J. Yost is registered with Medicare and accepts Medicare payments.
Publications
- Adapting a Cancer Literacy Measure for Use Among Navajo Women.
- Shared Decision Making for Antidepressants in Primary Care: A Cluster Randomized Trial.
- Correlation of the patient reported outcomes measurement information System with legacy outcomes measures in assessment of response to lumbar transforaminal epidural s...
- Was a decision made? An assessment of patient-clinician discordance in medical oncology encounters.
- Lymphedema After Surgery for Endometrial Cancer: Prevalence, Risk Factors, and Quality of Life.
- The Fuzzy Edge of CAM Use: Challenges in What Constitutes CAM Use in Self-Administered Questionnaires.
- A Brief Patient-Reported Outcomes Quality of Life (PROQOL) Instrument to Improve Patient Care.
- Norming plans for the NIH Toolbox.
- The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma.
- Development and Validation of a Self-Report Lower-Extremity Lymphedema Screening Questionnaire in Women.
- Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.
- Patient-reported outcomes in studies of complementary and alternative medicine: problems, solutions, and future directions.
- Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage Cancer patients.
- Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic Cancer.
- Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers.
- Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colo...
- Fertility preservation and adolescent Cancer patients: lessons from adult survivors of childhood Cancer and their parents.
- Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenoCarcinoma of the stomach: a Southwest Oncology Group study.
- Future trends in patient-reported outcomes assessment for patients with advanced-stage lung Cancer receiving targeted therapy.
- Patients' perceptions of quality of care for colorectal Cancer by race, ethnicity, and language.
- Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience.
- Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modif...
- A Systematic review of patient-reported measures of burden of treatment in three chronic diseases.
- Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell Carcinoma of the urothelium.
- Treatment of advanced renal cell Carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
- Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate Cancer: a phase II tri...
- Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced ...
- Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal Cancer: final results of a Minnie Pearl Ca...
- Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Netwo...
- Socioeconomic status and breast Cancer incidence in California for different race/ethnic groups.
- Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and ...
- A randomized validation study comparing embedded versus exTracted FACT Head and Neck Symptom Index scores.
- The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.
- General population and Cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G).
- Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI).
- Comparing SF-36 scores across three groups of women with different health profiles.
- A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast Cancer scale.
- Phase II trial of gemcitabine plus irinotecan in patients with esophageal Cancer: a Southwest Oncology Group (SWOG) trial.
- Application of robust statistical methods for sensitivity Analysis of health-related quality of life outcomes.
- Predictors of health-related quality of life in patients with colorectal Cancer.
- Quality-of-life and surgical treatments for rectal Cancer--a longitudinal analysis using the California Cancer Registry.
- Bilingual health literacy assessment using the Talking Touchscreen/la Pantalla Parlanchina: Development and pilot testing.
- Spiritual well-being and health-related quality of life in colorectal Cancer: a multi-site examination of the role of personal meaning.
- Acceptability of the talking touchscreen for health literacy assessment.
- Obstetric fistula: the ECWA Evangel VVF Center surgical experience from Jos, Nigeria.
- Health literacy assessment using talking touchscreen technology (Health LiTT): a new item response theory-based measure of health literacy.
Schools
University Of Michigan Medical School
Blodgett Meml Med Center
Vanderbilt University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Vanderbilt University -
University of Michigan Medical School
Hospital
-
Spectrum Health - Butterworth Hospital
Drug Facts
| NPI NUMBER | 1780685149 | |
| NPPES Provider LastName | YOST | |
| NPPES Provider FirstName | KATHLEEN | |
| NPPES Provider ZIPCode | 495032562 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1709.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 218.0 | |
| Percent Opioid Claims | 12.76 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1780685149 |
| Last Name Of The Provider | YOST |
| First Name Of The Provider | KATHLEEN |
| View All |
Similar Doctors
|
Dr. Madhuri V. Kakarala, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric D. Batts, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arthur H. Rossof, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin J. Bury, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn B. Alguire, MD
This Doctor is OpenDoctor Recommended.
|